Supernus Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$54.77
−$0.98 (−1.77%) 4:00 PM ET
After hours$54.73
−$0.04 (−0.06%) 4:21 AM ET
Prev closePrevC$55.75
OpenOpen$56.14
Day highHigh$56.32
Day lowLow$53.12
VolumeVol815,652
Avg volAvgVol842,517
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$3.14B
P/E ratio
-161.07
FY Revenue
$681.54M
EPS
-0.34
Gross Margin
88.61%
Sector
Healthcare
AI report sections
BULLISH
SUPN
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. shows strong positive price momentum over the past 6–12 months with the stock trading in the upper portion of its 52-week range and above key moving averages. At the same time, recent profitability has turned negative despite high gross margins and positive free cash flow, indicating a divergence between operating performance and cash generation. Short interest metrics and technical breakouts point to elevated positioning risk and potential for volatility even as news flow has been broadly constructive.
AI summarized at 3:16 AM ET, 2025-12-20
AI summary scores
INTRADAY:63SWING:72LONG:58
Volume vs average
Intraday (cumulative)
+4% (Above avg)
Vol/Avg: 1.04×
RSI
68.66(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
+0.03 (Strong)
MACD: 0.22 Signal: 0.19
Short-Term
+0.55 (Strong)
MACD: 1.21 Signal: 0.67
Long-Term
+0.40 (Strong)
MACD: 1.55 Signal: 1.15
Intraday trend score
74.92
LOW44.92HIGH79.42
Latest news
SUPN•12 articles•Positive: 5Neutral: 2Negative: 0
NeutralGlobeNewswire Inc.• Na
Supernus Pharmaceuticals to Participate in March Investor Conferences
Supernus Pharmaceuticals announced that management will participate in three major healthcare investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference (March 2), Jefferies Biotech on the Beach Summit (March 10), and Barclays 28th Annual Global Healthcare Conference (March 11). Live webcasts will be available for select presentations.
The announcement is routine corporate disclosure regarding conference participation. It demonstrates active investor engagement and market presence but contains no material business developments, financial results, or strategic announcements that would indicate positive or negative sentiment.
NeutralThe Motley Fool• Jonathan Ponciano
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
Aristotle Capital Boston reduced its holdings in Pharmaceuticals by 503,122 shares in Q3, decreasing its position value by approximately $10.9 million. Despite a 31% stock price increase over the past year, the company remains below its 2018 highs.
The stock has shown positive performance with 31% growth, but faces challenges with uneven profitability and remains below historical highs. The fund's partial sell-off suggests cautious investor outlook.
PositiveBenzinga• Globe Newswire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
Actively pursuing strategic acquisition of Sage Therapeutics, expanding its neuroscience portfolio and demonstrating corporate growth initiative
PositiveGlobeNewswire Inc.• N/A
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.
SUPNSupernus Pharmaceuticalsfinancial resultsconference callcentral nervous system diseases
Sentiment note
The article announces that Supernus Pharmaceuticals will host a conference call to discuss its financial results, indicating the company's ongoing business activities and performance.
PositiveGlobeNewswire Inc.• N/A
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, announced that its President and CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference.
SUPNSupernus Pharmaceuticalscentral nervous system diseasesPiper Sandler Healthcare Conference
Sentiment note
The article announces that Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will participate in a fireside chat at an industry conference, indicating the company's active involvement in the industry and potential growth opportunities.
PositiveGlobeNewswire Inc.• Transparency Market Research Inc.
Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc.
The global ADHD treatment market is expected to grow at a CAGR of 3.1% from 2024 to 2034, reaching $15.4 billion by 2034. The growth is driven by increased awareness of ADHD and ongoing research and development efforts.
LLYPFEJNJNVSADHDtreatment marketgrowthawareness
Sentiment note
Supernus Pharmaceutical, Inc. is listed as one of the key players in the ADHD treatment market, implying their involvement and potential to gain from the market's growth.
PositiveGlobeNewswire Inc.• N/A
Supernus Pharmaceuticals to Announce Second Quarter 2024 - GlobeNewswire
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will announce its Q2 2024 financial results and host a conference call on August 6, 2024.
The article announces that the company will report its financial and business results for the second quarter of 2024, indicating ongoing operations and performance.
UnknownZacks Investment Research• Zacks Equity Research
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
SUPN
UnknownGlobeNewswire Inc.• Supernus Pharmaceuticals, Inc.
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy
SUPNHealthResearch Analysis and ReportsClinical Study
UnknownGlobeNewswire Inc.• Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures.
SUPNCalendar of Events
UnknownZacks Investment Research• Zacks Equity Research
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SUPN
UnknownGlobeNewswire Inc.• Supernus Pharmaceuticals, Inc.
Supernus Announces First Quarter 2024 Financial Results
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
SUPNEarnings Releases and Operating Results
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
